Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.71 |
| ▸ | KDR | P35968 | 4/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | PRKACA | P17612 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.50 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.50 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.50 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.50 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.50 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3085669 | 0.83 | IDO1 (0.71) | IDO1MAP4K4KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5982431 | 0.70 | BRD4 (0.42) | IDO1BRD4KDM4ETSHRHSD17B10 | |
| SCHEMBL12670528 | 0.67 | — | — | |
| SCHEMBL5313030 | 0.67 | — | — | |
| SCHEMBL17248112 | 0.67 | IDO1 (0.44) | IDO1SMN1; SMN2 | |
| SCHEMBL268709 | 0.67 | IDO1 (0.44) | IDO1CHEK1DYRK1AKDM4EL3MBTL1 | |
| SCHEMBL4769715 | 0.66 | IDO1 (0.47) | IDO1BRD4KDM4ETSHRHSD17B10 | |
| SCHEMBL25077602 | 0.65 | ALDH1A1 (0.45) | BRD4KDM4ETSHRHSD17B10ALDH1A1 | |
| SCHEMBL12145232 | 0.65 | PTAFR (0.58) | KDRCHEK1MAP4K4CSF1RPRKACA | |
| SCHEMBL20893092 | 0.65 | CDK2 (0.40) | IDO1KDRCHEK1MAP4K4CSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8697065-B2 | Non-natural ribonuclease conjugates as cytotoxic agents | QUINTESSENCE BIOSCIENCES, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-8143232-B2 | Gene fusion targeted therapy | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-03-27 | — | — | US | disclosed |
| US-20120035244-A1 | PARP1 TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-02-09 | — | — | US | disclosed |
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-10-13 | — | — | US | disclosed |
| WO-2011103028-A2 | COMPOSITIONS AND METHODS FOR INHIBITING MMSET | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103011-A2 | GENE FUSION TARGETED THERAPY | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| WO-2011103016-A2 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-25 | — | — | WO | disclosed |
| US-7910621-B2 | Small molecule antagonists of XIAP family proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-03-22 | — | — | US | disclosed |
| US-20110020434-A1 | NANOPARTICLE ARSENIC-PLATINUM COMPOSITIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-27 | — | — | US | disclosed |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2008-01-24 | — | — | US | disclosed |
| US-4584305-A | Aiding the regression of neoplastic disease with 2,3,5,6-tetrahydro-6-phenylimidazo[2,1-b]thiazole | JANSSEN PHARMACEUTICA N.V. (BE) | 1986-04-22 | — | — | US | disclosed |
| US-3878222-A | METHODS OF PREPARING SUBSTITUTED IMIDAZOTHIAZOLIUM COMPOUNDS | AMERICAN CYANAMID CO | 1975-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251216-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EZH2 | EZH2, BMI1, EZH1 | IDO1 4170/4885KDR 3930/4885CHEK1 2721/4885 |
| US-20080021095-A1 | Small Molecule Antagonists of Xiap Family Proteins | XIAP, BIRC5, BIRC3 | IDO1 2306/4885KDR 4312/4885CHEK1 1548/4885 |
| US-20120035244-A1 | PARP1 TARGETED THERAPY | PARP1, PARP11, PARP12 | IDO1 3459/4885KDR 716/4885CHEK1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.